The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 29, 2024

Filed:

May. 18, 2017
Applicant:

Modernatx, Inc., Cambridge, MA (US);

Inventors:

Kerry Benenato, Sudbury, MA (US);

Stephen Hoge, Brookline, MA (US);

Paolo Martini, Boston, MA (US);

Iain Mcfadyen, Arlington, MA (US);

Vladimir Presnyak, Manchester, NH (US);

Ding An, Waban, MA (US);

Ellalahewage Sathyajith Kumarasinghe, Harvard, MA (US);

Assignee:

ModernaTX, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); A61K 9/00 (2006.01); A61K 9/51 (2006.01); A61K 47/00 (2006.01); A61K 47/14 (2017.01); A61K 47/16 (2006.01); A61K 47/22 (2006.01); A61K 47/24 (2006.01); C12N 15/88 (2006.01); A61K 9/127 (2006.01); A61K 47/10 (2017.01); A61K 47/28 (2006.01); C07K 14/705 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0066 (2013.01); A61K 9/51 (2013.01); A61K 47/14 (2013.01); A61K 47/16 (2013.01); A61K 47/22 (2013.01); A61K 47/24 (2013.01); A61K 48/0041 (2013.01); C12N 15/88 (2013.01); A61K 9/1271 (2013.01); A61K 9/5123 (2013.01); A61K 47/10 (2013.01); A61K 47/28 (2013.01); C07K 14/705 (2013.01);
Abstract

The invention relates to mRNA therapy for the treatment of Alagille syndrome (ALGS), mRNAs for use in the invention, when administered in vivo, encode JAGGED 1 (JAG1), isoforms thereof functional fragments thereof, and fusion proteins comprising JAG1, mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of JAG1 expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient JAG1 activity in subjects.


Find Patent Forward Citations

Loading…